clinical consequences of the slow-acetylator phenotype include increased susceptibility to systemic lupus erythematosus induced by procainamide and hydralazine , peripheral neuropathy induced by isoniazid , hydralazine , and dapsone , and sulfasalazine-induced dose-related leukopenia , nausea , vomiting , headache , and vertigo .
C0024141
systemic lupus erythematosus
C0033216
procainamide